Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 710-716

  Costello, Brian A ^a   Borad, Mitesh J ^a   Qi, Yingwei ^a   Kim, George P ^a   Northfelt, Donald W ^a   Erlichman, Charles ^a   Alberts, Steven R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholangiocarcinoma; Cisplatin; Everolimus; Gallbladder cancer; Gemcitabine; Phase I

Indexed keywords

CISPLATIN; EVEROLIMUS; GEMCITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; RAPAMYCIN;

ADULT; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PANCREAS CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASMS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EVEROLIMUS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; SIROLIMUS;

EID: 84904535924     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0096-3     Document Type: Article

References (17)

1. Novartis. RAD001 Investigators Brochure (2011)
2. O'Donnell A, Faivre S, Burris HA et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-95
3. Tanaka C, O'Reilly T, Kovarik JM et al (2008) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-602
4. O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA (2011) Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 22:58-78
5. Castro MP(1998) Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer 82:639-41
6. Gallardo J, Fodor M, Gamargo C, Orlandi L (1998) Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer 83:2419-21 (Pubitemid 28533513)
7. Kovarik JM, Sabia HD, Figueiredo J et al (2001) Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 70:425-30 (Pubitemid 33135321)
8. Peveling-Oberhag J, Zeuzem S, Yong WP et al (2013) Effects of hepatic impairment on the pharmacokinetics of everolimus: a singledose, open-label parallel-group study. Clin Ther 35:215-25
9. Ito D, Fujimoto K, Mori T et al (2006) In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 118:2337-43
10. Pacey S, Rea D, Steven N et al (2004) Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers. J Clin Oncol 22:3120
11. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl JMed 362:1273-81
12. Bukowski RM, Leichman LP, Rivkin SE (1983) Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest oncology group study. Eur J Cancer Clin Oncol 19:721-3 (Pubitemid 13058367)
13. Ekstrom K, Hoffman K, Linne T, Eriksson B, Glimelius B (1998) Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study. Oncol Rep 5:931-4 (Pubitemid 28270698)
14. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14:2306-10 (Pubitemid 26324154)
15. Okada S, Ishii H, Nose H et al (1994) A phase II study of cisplatin in patients with biliary tract carcinoma. Oncol 51:515-7 (Pubitemid 24347034)
16. Taal BG, Audisio RA, Bleiberg H et al (1993) Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 4:607-9 (Pubitemid 23257561)
17. Fury MG, Sherman E, Haque S, et al. (2011). A phase I study of daily everolimus plus low-dose weekly cisplatin for patientswith advanced solid tumors. Cancer Chemother Pharmacol